secwatch.observer — SEC 8-K summary
======================================

Issuer:     Acrivon Therapeutics, Inc. (ACRV)
CIK:        0001781174
Form:       8-K
Filed at:   2023-08-11T23:59:59+00:00
Accession:  0001193125-23-209745
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Acrivon posts Q2 2023 net loss of $13.9M; cash $151M funds ops into 2025
------------------------------------------------------------------------

- Net loss $13.9M vs $5.8M in Q2 2022; R&D expenses $10.5M, up from $4.1M.
- Cash, equivalents and marketable securities $151.0M as of June 30, 2023.
- Registrational-intent Phase 2 trial of ACR-368 enrolling; initial data expected H2 2023.
- FDA granted two Fast Track designations for ACR-368 in OncoSignature-positive ovarian and endometrial cancers.
- Appointed Charles Baum to board and Adam Levy as SVP IR and corporate affairs.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1781174/000119312523209745/0001193125-23-209745-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1781174/000119312523209745/d337383d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-23-209745

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer